Categories

Ukoniq (umbralisib): Drug Safety Communication – FDA Investigating Possible Increased Risk of Death with Lymphoma

The FDA is investigating a possible increased risk of death with the cancer medicine Ukoniq (umbralisib) approved to treat two specific types of lymphomas, which are cancers that affect the body’s immune system.

http://www.fda.gov/safety/medical-product-safety-information/ukoniq-umbralisib-drug-safety-communication-fda-investigating-possible-increased-risk-death-lymphoma

 
Categories

Biosimilar and interchangeable biosimilar products – USFDA Curriculum Materials for Health Care Degree Programs

FDA’s curriculum materials are intended to help educate students in health care professional degree programs, for medicine, nursing, physician assistants, and pharmacy, as well as practicing professionals, to improve understanding of biosimilar and interchangeable biosimilar products and the regulatory approval pathway in the United States.

For more information go to https://www.fda.gov/drugs/biosimilars/curriculum-materials-health-care-degree-programs-biosimilars

 
Categories

Casos, hospitalizaciones y fallecimientos COVID-19 continúan registrando alzas

Casos, hospitalizaciones y fallecimientos COVID-19 continúan registrando alzas

Casos, hospitalizaciones y fallecimientos COVID-19 continúan registrando alzasMartes 1 de febrero, 2022. La semana epidemiológica 4 que abarcó del 23 al 29 de enero registró 39.611 casos de COVID-19

https://www.ministeriodesalud.go.cr/index.php/centro-de-prensa/noticias/746-noticias-2021/2266-casos-hospitalizaciones-y-fallecimientos-covid-19-continuan-registrando-alzas